Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck Azilect treatment yields positive trial results

Lundbeck Azilect treatment yields positive trial results

24th September 2009

Lundbeck has announced study results relating to its Parkinson’s disease therapy Azilect (rasagiline) which show that early treatment yields the best outcome for patients.

The data shows that early-start patients receiving Azilect as a drug to control the condition in doses of 1 mg per day experienced a superior benefit over 18 months compared with those who began the exact same treatment nine months later.

Azilect is the first ever therapy for Parkisnon’s disease that has demonstrated effectiveness in early prevention in a delayed-start study.

“A therapy that slows or stops disease progression is the greatest unmet need in the treatment of patients with Parkinson’s disease. Current therapies do not prevent the development of disability in such patients,” said Professor Warren Olanow, managing director of the department of neurology at the Mount Sinai School of Medicine and co-principal investigator of the study.

In August, Lundbeck received approval from the Food and Drug Administration for Sabril (vigabatrin), representing the first-ever time the regulating body had authorised a treatment for infantile spasms.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.